BIOMARIN PHARMACEUTICAL INC OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of -$587.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2015-12-31 was -$1.90M.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2015-09-30 was -$2.95M, a 297.66% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2015-06-30 was -$890.00K, a 212.66% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2015-03-31 was $4.16M, a 406.70% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2025 was -$587.00K.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2024 was -$289.00K.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2023 was -$3.92M, a 220.79% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2022 was $3.25M, a 103.45% increase from fiscal 2021.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$587.00K 10-K · filed 2026-02-26 | |||||||
| 2024-12-31 | -$289.00K 10-K · filed 2026-02-26 | |||||||
| 2023-12-31 | -$3.92M 10-K · filed 2026-02-26 | |||||||
| 2022-12-31 | $3.25M 10-K · filed 2025-02-24 | |||||||
| 2021-12-31 | $1.60M 10-K · filed 2024-02-26 | |||||||
| 2020-12-31 | -$227.00K 10-K · filed 2023-02-27 | $227.00K 10-K · filed 2021-02-26 | ||||||
| 2019-12-31 | -$1.64M 10-K · filed 2022-02-25 | $1.64M 10-K · filed 2020-02-27 | ||||||
| 2018-12-31 | $413.00K 10-K · filed 2021-02-26 | |||||||
| 2017-12-31 | -$272.00K 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | -$4.41M 10-K · filed 2019-02-28 | |||||||
| 2015-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$4.85M derived: sum of 2 quarters · filed 2018-02-26 | -$5.74M derived: sum of 3 quarters · filed 2018-02-26 | -$1.58M 10-K · filed 2018-02-26 | ||||
| 2015-09-30 | -$2.95M 10-Q · filed 2015-11-02 | -$3.84M derived: sum of 2 quarters · filed 2015-11-02 | $319.00K 10-Q · filed 2015-11-02 | $144.00K derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | -$890.00K 10-Q · filed 2015-08-05 | $3.27M 10-Q · filed 2015-08-05 | $3.10M derived: sum of 3 quarters · filed 2017-02-27 | $4.59M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $4.16M 10-Q · filed 2015-05-05 | $3.98M derived: sum of 2 quarters · filed 2017-02-27 | $5.48M derived: sum of 3 quarters · filed 2017-02-27 | $6.27M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | -$175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.32M derived: sum of 2 quarters · filed 2017-02-27 | $2.11M derived: sum of 3 quarters · filed 2017-02-27 | $2.93M 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $1.49M 10-Q · filed 2015-11-02 | -$1.49M 10-Q · filed 2014-10-28 | $2.28M derived: sum of 2 quarters · filed 2015-11-02 | $3.11M 10-Q · filed 2015-11-02 | -$3.10M 10-Q · filed 2014-10-28 | $12.86M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $790.00K 10-Q · filed 2015-08-05 | -$791.00K 10-Q · filed 2014-07-31 | $1.61M 10-Q · filed 2015-08-05 | -$1.61M 10-Q · filed 2014-07-31 | $11.37M derived: sum of 3 quarters · filed 2016-02-29 | $6.07M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | $821.00K 10-Q · filed 2015-05-05 | -$821.00K 10-Q · filed 2014-05-02 | $10.58M derived: sum of 2 quarters · filed 2016-02-29 | $5.28M derived: sum of 3 quarters · filed 2016-02-29 | $4.48M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $9.76M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $4.46M derived: sum of 2 quarters · filed 2016-02-29 | $3.65M derived: sum of 3 quarters · filed 2016-02-29 | $3.54M 10-K · filed 2016-02-29 | -$3.54M 10-K · filed 2014-02-26 | |||
| 2013-09-30 | -$5.30M 10-Q · filed 2014-10-28 | -$6.10M derived: sum of 2 quarters · filed 2014-10-28 | -$6.22M 10-Q · filed 2014-10-28 | |||||
| 2013-06-30 | -$805.00K 10-Q · filed 2014-07-31 | -$925.00K 10-Q · filed 2014-07-31 | ||||||
| 2013-03-31 | -$120.00K 10-Q · filed 2014-05-02 | |||||||
| 2012-12-31 | $140.00K 10-K · filed 2015-03-02 | -$140.00K 10-K · filed 2013-02-26 | ||||||
| 2011-12-31 | $229.00K 10-K · filed 2014-02-26 | -$229.00K 10-K · filed 2013-02-26 | ||||||
| 2010-12-31 | $390.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |